✦ LIBER ✦

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial

✍ Scribed by J. H. ALEXANDER; H. YANG; R. C. BECKER; K. KODAMA; S. GOODMAN; C. K. DYKE; N. S. KLEIMAN; J. S. HOCHMAN; P. B. BERGER; E. A. COHEN; A. M. LINCOFF; J. R. BURTON; E. G. BOVILL; C. KAWAI; P. W. ARMSTRONG; R. A. HARRINGTON; THE XaNADU-ACS INVESTIGATORS

Book ID: 109148702
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 240 KB
Volume: 3
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2004.01081.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of abciximab on evolution of l

Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial

✍ Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 257 KB

Prediction of clinical outcome in patien

Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels

✍ Rudolf Jarai; Nelly Iordanova; Robert Jarai; Ferenc Jarai; Annamaria Raffetseder 📂 Article 📅 2007 🏛 Springer Vienna 🌐 English ⚖ 241 KB